Gene therapies, uncertainty, and decision-making: thinking about the last mile at the first step

References

• Hanna E, Toumi M, Dussart C, et al. Funding breakthrough therapies: A systematic review and recommendation. Health Policy. 2018;122:217–229. doi: 10.1016/j.healthpol.2017.11.012
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Aebersold P, Cornetta K, et al. Gene transfer into humans — immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med. 1990;323(9):570–578. doi: 10.1056/NEJM199008303230904
   PubMed Web of Science ®Google Scholar
• “U.S. National Library of Medicine“ ClinicalTrials.Gov.
   Google Scholar
• Gottlieb S Statement from FDA Commissioner Scott Gottlieb, M.D., Marks P. Director of the center for biologics evaluation and research on new policies to advance development of safe and effective cell and gene therapies. Administration, USFD. Montgomery County: (MD), 2019.
   Google Scholar
• Eder C, Wild C. Technology forecast: advanced therapies in late clinical research, EMA approval or clinical application via hospital exemption. J Mark Access Health Policy. 2019;7(1):1600939. doi: 10.1080/20016689.2019.1600939
   PubMedGoogle Scholar
• Hollier-Hann G, Cork D, Ralston S, et al. Health technology assessment of gene therapies for inherited genetic disorders in the US and Europe. Value Health. 2018;21:S210. doi: 10.1016/j.jval.2018.04.1421
   PubMedGoogle Scholar
• Amanda Whittal EI, Hutchings A. Exploring the economics of gene therapy innovation and price. London, UK: Dolon Ltd; 2022. p. 18. https://bit.ly/3AhEoG1
   Google Scholar
• Goncalves E. Value-based pricing for advanced therapy medicinal products: emerging affordability solutions. Eur J Health Econ. 2021;23(2):155–163. doi: 10.1007/s10198-021-01276-2
   PubMed Web of Science ®Google Scholar
• Carr DR, Bradshaw SE. Gene therapies: The challenge of super-high-cost treatments and how to pay for them. Regen Med. 2016;11(4):381–393. doi: 10.2217/rme-2016-0010
   PubMed Web of Science ®Google Scholar
• Salzman R, Cook F, Hunt T, et al. Addressing the value of gene therapy and enhancing patient access to transformative treatments. Mol Ther. 2018;26(12):2717–2726. doi: 10.1016/j.ymthe.2018.10.017
   PubMed Web of Science ®Google Scholar
• Barlow J, Bens C, Brent T, et al. AMCP partnership forum: designing benefits and payment models for innovative high-investment medications. J Manag Care Spec Pharm. 2019;25:156–162.
   PubMed Web of Science ®Google Scholar
• Drummond MF, Neumann PJ, Sullivan SD, et al. Analytic considerations in applying a general economic evaluation reference case to gene therapy. Value Health. 2019;22(6):661–668. doi: 10.1016/j.jval.2019.03.012
   PubMed Web of Science ®Google Scholar
• Jørgensen J, Kefalas P. Annuity payments can increase patient access to innovative cell and gene therapies under England’s net budget impact test. J Mark Access Health Policy. 2017;5(1):1355203. doi: 10.1080/20016689.2017.1355203
   PubMedGoogle Scholar
• Cook K, Forbes SP, Adamski K, et al. Assessing the potential cost-effectiveness of a gene therapy for the treatment of hemophilia a. J Med Econ. 2020;23(5):501–512. doi: 10.1080/13696998.2020.1721508
   PubMed Web of Science ®Google Scholar
• Hettle R, Corbett M, Hinde S, et al. The assessment and appraisal of regenerative medicines and cell therapy products: An exploration of methods for review, economic evaluation and appraisal. Health Technol Assess. 2017;21(7):1–204. doi: 10.3310/hta21070
   PubMed Web of Science ®Google Scholar
• Angelis A, Naci H, Hackshaw A. Recalibrating health technology assessment methods for cell and gene therapies. PharmacoEconomics. 2020;38(12):1297–1308. doi: 10.1007/s40273-020-00956-w
   PubMed Web of Science ®Google Scholar
• Project” MNF. Designing precision financing for cures. In Financing and reimbursement of cures in the US. Initiatives. MNDDP Cambridge, MA: Massachusetts Institute of Technology; 2018. p. 1–3. https://newdigs.tuftsmedicalcenter.org/designing-precision-financing-for-cures/
   Google Scholar
• Claxton K, Palmer S, Longworth L, et al. A comprehensive algorithm for approval of health technologies with, without, or only in research: the key principles for informing coverage decisions. Value Health. 2016;19(6):885–891. doi: 10.1016/j.jval.2016.03.2003
   PubMed Web of Science ®Google Scholar
• ten Ham RMT, Hövels AM, Klungel OH, et al. Development and regulation of gene and cell-based therapies in europe: a quantification and reflection. Trends Pharmacol Sci. 2020;41(2):67–71. doi: 10.1016/j.tips.2019.11.007
   PubMed Web of Science ®Google Scholar
• Pasi KJ, Rangarajan S, Mitchell N, et al. Multiyear follow-up of AAV5-Hfviii-SQ gene therapy for hemophilia a. N Engl J Med. 2020;382(1):29–40. doi: 10.1056/NEJMoa1908490
   PubMed Web of Science ®Google Scholar
• Ozelo MC, Mahlangu J, Pasi KJ, et al. Valoctocogene roxaparvovec gene therapy for hemophilia a. N Engl J Med. 2022;386(11):1013–1025. doi: 10.1056/NEJMoa2113708
   PubMed Web of Science ®Google Scholar
• Rothe M, Modlich U, Schambach A. Biosafety challenges for use of lentiviral vectors in gene therapy. Curr Gene Ther. 2013;13(6):453–468. doi: 10.2174/15665232113136660006
   PubMed Web of Science ®Google Scholar
• CfMPfHUC. Guideline on safety and efficacy follow-up and risk management of advanced therapy medicinal products. EMA London: (UK); 2018. https://www.ema.europa.eu/documents/scientific-guideline/guideline-safety-efficacy-follow-risk-management-advanced-therapy-medicinal-products_en.pdf
   Google Scholar
• Garrison LP, Kamal-Bahl S, Towse A. Toward a broader concept of value: identifying and defining elements for an expanded cost-effectiveness analysis. Value Health. 2017;20(2):213–216. doi: 10.1016/j.jval.2016.12.005
   PubMed Web of Science ®Google Scholar
• Gardner J, Webster A, Barry J. Anticipating the clinical adoption of regenerative medicine: Building institutional readiness in the UK. Regen Med. 2018;13(1):29–39. doi: 10.2217/rme-2017-0121
   PubMed Web of Science ®Google Scholar
• Gardner J, Faulkner A, Mahalatchimy A, et al. Are there specific translational challenges in regenerative medicine? Lessons from other fields. Regen Med. 2015;10(7):885–895. doi: 10.2217/rme.15.50
   PubMed Web of Science ®Google Scholar
• Hopkins MM, Martin PA, Nightingale P, et al. The myth of the biotech revolution: An assessment of technological, clinical and organisational change. Res Policy. 2007;36(4):566–589. doi: 10.1016/j.respol.2007.02.013
   Web of Science ®Google Scholar
• Shire SJ, Shahrokh Z, Liu J. Challenges in the development of high protein concentration formulations. J Pharmaceut sci. 2004;93(6):1390–1402. doi: 10.1002/jps.20079
   PubMed Web of Science ®Google Scholar
• Shire SJ. Formulation and manufacturability of biologics. Curr Opin Biotechnol. 2009;20(6):708–714. doi: 10.1016/j.copbio.2009.10.006
   PubMed Web of Science ®Google Scholar
• Edlin R, Hall P, Wallner K, et al. Sharing risk between payer and provider by leasing health technologies: an affordable and effective reimbursement strategy for innovative technologies? Value Health. 2014;17(4):438–444. doi: 10.1016/j.jval.2014.01.010
   PubMed Web of Science ®Google Scholar
• Persson KSC U, Jonsson B. Alternative payment models in haemophilia treatment. Lund:IHE; 2016. https://ihe.se/wp-content/uploads/2016/12/IHE-Report-2016_10_.pdf
   Google Scholar
• Quinn C, Ciarametaro M, Sils B, et al. Value-based performance arrangements for chronic conditions: an economic simulation of medicaid drug rebate program reforms. Expert Rev Pharmacoecon Outcomes Res. 2023;23(5):535–546. doi: 10.1080/14737167.2023.2193331
   PubMed Web of Science ®Google Scholar
• Project” MNF. How can self-insured employers prepare for the portfolio impact of highcost gene therapies coming to market? In Financing and reimbursement of cures in the US. Cambridge, MA:Massachusetts Institute of Technology; 2022. https://newdigs.tuftsmedicalcenter.org/how-can-self-insured-employers-prepare-for-the-portfolio-impact-of-highcost-gene-therapies-coming-to-market/
   Google Scholar
• Trusheim MR, Cassidy WM, Bach PB. Alternative state-level financing for hepatitis C treatment-the “netflix model”. JAMA. 2018;320(19):1977–1978. doi: 10.1001/jama.2018.15782
   PubMed Web of Science ®Google Scholar
• van Nimwegen KJM, Lilford RJ, van der Wilt GJ, et al. Headroom beyond the quality- adjusted life-year: the case of complex pediatric neurology. Int J Technol Assess Health Care. 2017;33(1):5–10. doi: 10.1017/S0266462317000046
   PubMed Web of Science ®Google Scholar